Methylphenidate is recommended as the first-line pharmacological treatment in children and a first-line pharmacological treatment in adults.5
Indication6

  • Medikinet XL is indicated for the treatment of ADHD in children aged 6 years and over and adults.
  • Medikinet XL can be continued in adult patients who have shown a clear benefit from treatment with Medikinet XL in childhood and/or adolescence.
  • Medikinet XL is licensed for newly diagnosed adult ADHD patients.
CHILDREN: Medikinet XL should be given in the morning with or after breakfast.
ADULTS: Medikinet XL should be given in the morning and at lunchtime with or after the meals.
Dosage Range6
Medikinet XL: “As little as possible, as much as necessary”

Capsules are available as 5mg, 10mg, 20mg, 30mg, 40mg, 50mg and 60mg offering the broadest range of methylphenidate presentations. Medikinet XL 5mg allows fine-tuning of the methylphenidate dose to meet the individual needs of the patient.

Sprinkle Option6

The Medikinet XL capsule may be opened, and the capsule contents sprinkled onto a small amount (tablespoon) of apple sauce or similar soft food.

Formulation6

  • Medikinet XL combines the advantages of both immediate-release and extended-release formulations of methylphenidate.
  • 50% of the Medikinet XL dose is provided by the immediate‑release component and 50% of the dose is provided by the extended-release component.
  • When taken after breakfast, the immediate-release portion of Medikinet XL dissolves rapidly and results in an initial peak plasma concentration.
  • After passing through the stomach and into the small intestine, the extended-release portion of the hard capsule releases its methylphenidate resulting in a second rise in plasma concentration approximately 3 hours later.
  • It is important to take Medikinet XL with, or after food, to prevent the extended-release component releasing prematurely.

Symptom Control6

The 50:50 release profile of Medikinet XL mimics 2 equal doses of immediate-release methylphenidate given at breakfast and at lunchtime, providing balanced morning and afternoon symptom control.

References

5. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE Guideline 87. NICE, 2018. Available at: www.nice.org.uk/guidance/ng87 (Accessed May 2021)

6. Medikinet XL Summary of Product Characteristics (SmPC) (Accessed January 2021)